Literature DB >> 9392568

Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler.

R J Adams1, V C McKie, E M Carl, F T Nichols, R Perry, K Brock, K McKie, R Figueroa, M Litaker, S Weiner, D Brambilla.   

Abstract

Stroke is an important complication of sickle cell disease. Stroke prediction is clinically important because it offers the possibility of primary prevention. In 1992, transcranial Doppler (TCD) evidence of elevated intracranial internal carotid or middle cerebral artery velocity was demonstrated to be associated strongly with an increased risk of ischemic stroke. This study extends the original study and includes 125 more children, longer follow-up, and intracranial hemorrhage in the stroke-risk model. Elevated time averaged mean maximum blood flow velocity, especially when velocity is 200 cm/sec or greater by TCD, was associated strongly with stroke risk. The cases not predicted by TCD point to the need for more information on the optimal timing of TCD surveillance for stroke risk.

Entities:  

Mesh:

Year:  1997        PMID: 9392568     DOI: 10.1002/ana.410420505

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  74 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

Review 2.  Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Authors:  Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2005-02-10

3.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Sickle cell disease: reference values and interhemispheric differences of nonimaging transcranial Doppler blood flow parameters.

Authors:  M Arkuszewski; J Krejza; R Chen; J L Kwiatkowski; R Ichord; R Zimmerman; K Ohene-Frempong; L Desiderio; E R Melhem
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

Review 5.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

6.  Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease.

Authors:  Henrietta Enninful-Eghan; Reneé H Moore; Rebecca Ichord; Kim Smith-Whitley; Janet L Kwiatkowski
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

7.  Understanding sickle cell brain drain.

Authors:  Monica L Hulbert; Andria L Ford
Journal:  Blood       Date:  2014-08-07       Impact factor: 22.113

8.  Genetic endothelial systems biology of sickle stroke risk.

Authors:  Liming Chang Milbauer; Peng Wei; Judy Enenstein; Aixiang Jiang; Cheryl A Hillery; J Paul Scott; Stephen C Nelson; Vidya Bodempudi; James N Topper; Ruey-Bing Yang; Betsy Hirsch; Wei Pan; Robert P Hebbel
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

Review 9.  Transcranial Doppler ultrasonography: From methodology to major clinical applications.

Authors:  Antonello D'Andrea; Marianna Conte; Massimo Cavallaro; Raffaella Scarafile; Lucia Riegler; Rosangela Cocchia; Enrica Pezzullo; Andreina Carbone; Francesco Natale; Giuseppe Santoro; Pio Caso; Maria Giovanna Russo; Eduardo Bossone; Raffaele Calabrò
Journal:  World J Cardiol       Date:  2016-07-26

10.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.